(Q51355872)

4 April 2018

title

Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjects. (English)

1 reference

4 April 2018

1 reference

D L Cutler

1

1 reference

4 April 2018

A Tendolkar

series ordinal

2

1 reference

4 April 2018

I D Grachev

series ordinal

3

1 reference

4 April 2018

publication date

7 June 2012

1 reference

4 April 2018

Journal of Clinical Pharmacy and Therapeutics

published in

1 reference

4 April 2018

volume

37

1 reference

4 April 2018

issue

5

1 reference

4 April 2018

page(s)

578-587

1 reference

4 April 2018

Epidemiology of Parkinson's disease

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2012.01349.X

Medical treatment of Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2012.01349.X

Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2012.01349.X

Functional architecture of basal ganglia circuits: neural substrates of parallel processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2012.01349.X

Adenosine, adenosine A 2A antagonists, and Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2012.01349.X

Adenosine A2A receptors and basal ganglia physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2012.01349.X

Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2012.01349.X

Blocking striatal adenosine A2A receptors: a new strategy for basal ganglia disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2012.01349.X

Opposing actions of adenosine A2a and dopamine D2 receptor activation on GABA release in the basal ganglia: evidence for an A2a/D2 receptor interaction in globus pallidus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2012.01349.X

Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2012.01349.X

Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2012.01349.X

Characterization of the Potent and Highly Selective A(2A) Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyraz olo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2012.01349.X

Adenosine A2 receptors modulate haloperidol-induced catalepsy in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2012.01349.X

Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2012.01349.X

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2012.01349.X

A(2A) adenosine receptors in human peripheral blood cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2012.01349.X

Localization and action of adenosine A2a receptors in regions of the brainstem important in cardiovascular control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2012.01349.X

Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2012.01349.X

10.1111/J.1365-2710.2012.01349.X

21 January 2018

Identifiers

DOI

1 reference

4 April 2018

1 reference

4 April 2018